Direct brain infusion of glial cell line–derived neurotrophic factor in Parkinson disease

By S. Gill, N. Patel, G. Hotton, K. O’Sullivan, R. McCarter, M. Bunnage, D. Brooks, C. Svendsen, P. Heywood. Nature Medicine, 2003

1,320 citations recorded by the source corpus.

Subfields: Cellular and Molecular Neuroscience, Neurology

View Paper: https://www.semanticscholar.org/paper/d3dd9f321922f1cbea621b356ea0f5d48628a6a7

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Cellular and Molecular Neuroscience

In Neurology

Citations in the corpus

A phase 1 clinical trial of nerve growth factor gene therapy for Alzheimer disease (2005, result): “The findings of improvement in PET activity and a possible effect on clinical outcome mirror recent findings after delivery of a dopaminergic growth factor, glial cell line–derived neurotrophic factor (GDNF), in Parkinson diseas”
Novel functions and signalling pathways for GDNF (2003, background): “This study demonstrated that direct intra-putamenal GDNF delivery in patients with Parkinson’s disease can be tolerated for at least 1 year, leads to a significant increase in dopamine storage in the putamen, and improves the patient’s clinical condition (Gill et al., 2003).”
The subthalamic nucleus in the context of movement disorders. (2004, background): “These include the administration of dopaminergic agonists and glutamate blockers, focal delivery of neurothrophic factors, change in the phenotype of STN neurons, lesions and high frequency stimulation of the STN (Bergman et al., 1990; Aziz et al., 1991; Klockgether et al., 1991; Wichmann et al., 19”
Metabotropic glutamate receptors: From the workbench to the bedside (2010, background): “GDNF is a potent prosurvival factor for nigral dopaminergic neurons (Lin et al., 1993), and intraputaminal infusion of GDNF attenuated parkinsonian symptoms in two phase-I clinical trials (Gill et al., 2003; Slevin et al., 2005).”
Parkinson's Disease Mechanisms and Models (2003, background): “It is then converted to MPP (probably bystudies form the basis for current attempts to use GDNF spontaneous oxidation), the active toxic molecule, andin PD patients (Gill et al., 2003).”
GDNF, NGF and BDNF as therapeutic options for neurodegeneration. (2013, background): “undertook the first open-label study of continuous intraputamenal delivery of GDNF via stereotactically-placedmicrocatheters attached to a subcutaneous infusion pump placed in the anterior abdominal wall (Gill et al., 2003).”
Classic toxin-induced animal models of Parkinson’s disease: 6-OHDA and MPTP (2004, background): “Chronic GDNF infusion into the dorsal putamen, via programmable pumps, resulted in improved motor function in all patients and limited side effects were observed (Gill et al. 2003).”
Molecular mechanisms and potential therapeutical targets in Huntington's disease. (2010, background): “However, there is a serious drawback associated with this administration route due to the generation of a steep concentration gradient, originating from the infusion point, which could lead to alteration of the infused tissue and the development of adverse effects, such as edema (209).”